Semaglutide may show promise for smoking cessation
New use of semaglutide was associated with a lower risk for medical care related to tobacco use disorder (TUD) in smokers with type 2 diabetes compared with 7… read more.
New use of semaglutide was associated with a lower risk for medical care related to tobacco use disorder (TUD) in smokers with type 2 diabetes compared with 7… read more.
A new USC study suggests that publicly insured individuals who are most likely to benefit from new drugs for diabetes and obesity are less likely to get them than those with… read more.
A recent study of more than 2,700 older Canadians reported older adults with diabetes faced a heightened risk of depression during the COVID-19 pandemic. In this cohort, almost 50%… read more.
A nationwide study found a marked increase in new GLP-1RA prescriptions over the last decade, particularly since 2020. Semaglutide was the most prescribed GLP-1RA, by far, in 2023…. read more.
Irregular sleep duration appears to be associated with an increased risk of diabetes, researchers reported on July 17, 2024 in Diabetes Care. “Our study identified a modifiable lifestyle… read more.
A large retrospective analysis of the cognitive effects of various antidiabetic treatments has disclosed that the risks of dementia and Alzheimer’s disease (AD) were significantly lower in patients… read more.
Combination treatment of diabetes with a sodium glucose co-transporter 2 inhibitor (SGLT2) and a glucagon-like peptide-1 receptor agonist (GLP1-RA) appears to also offer protection against heart and kidney… read more.
Roche announced four-year data from the RHONE-X extension study. The study met all primary endpoints, showing that Vabysmo (faricimab) was well tolerated in people with diabetic macular edema… read more.
Novo Nordisk announced that the FDA has issued a Complete Response Letter covering the Biologics License Application for once-weekly basal insulin icodec for the treatment of diabetes mellitus…. read more.
A new study led by investigators from Mass Eye and Ear found that patients prescribed semaglutide (as Ozempic or Wegovy) for diabetes or weight loss had a higher risk of… read more.
Roche announced that it has received the CE Mark for its Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution. This significant milestone paves the way for the solution to… read more.
AstraZeneca’s Farxiga (dapagliflozin) has been approved by the FDA to improve glycaemic control in paediatric patients with type-2 diabetes (T2D) aged 10 years and older. The FDA approval… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.